NCT02916420View on ClinicalTrials.gov

Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma

PHASE3UnknownINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2019

Conditions
Multiple Myeloma
Interventions
DRUG

Pomalidomide

4mg/day, d1-d21, 28 days per cycle

DRUG

Dexamethasone

≤70 years,40mg/day; \>70 years,20mg/day, d1、d8、d15、d22, 28 days per cycle

Trial Locations (1)

Unknown

RECRUITING

Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin

Sponsors
All Listed Sponsors
lead

Jiangsu Simcere Pharmaceutical Co., Ltd.

INDUSTRY